PEG-asparaginase

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 12, 2007, Pages 1977-1984

  Fu, Cecilia H ^a   Sakamoto, Kathleen M ^b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

ALL; Clinical trial; Immunogenicity; Metabolism; Pharmacokinetic; Resistance; Safety

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; ASPARAGINASE MACROGOL; ASPARAGINE; DOXORUBICIN; ESSENTIAL AMINO ACID; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING DISORDER; BODY WEIGHT DISORDER; BRONCHOSPASM; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL TRIAL; COMA; CONFUSION; COVALENT BOND; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESCHERICHIA COLI; FEASIBILITY STUDY; GASTROINTESTINAL TOXICITY; HALLUCINATION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERSENSITIVITY REACTION; HYPOALBUMINEMIA; IMMUNOGENICITY; INSULIN BLOOD LEVEL; IRRITABILITY; LEUKEMIA CELL; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PANCREATITIS; PROTEIN DEPLETION; PROTEIN SYNTHESIS INHIBITION; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOEMBOLISM; THROMBOSIS; UNSPECIFIED SIDE EFFECT; URTICARIA; VEIN THROMBOSIS; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; CONTROLLED CLINICAL TRIALS; DRUG APPROVAL; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, ACUTE; POLYETHYLENE GLYCOLS;

EID: 34548224598     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.12.1977     Document Type: Article

References (54)

1. ETTINGER LJ, KURTZBERGJ, VOUTE PA, JURGENS H, HALPERN SL: An open-labeled, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer (1995) 75:1176-1181.
2. ASSELIN BL, WHITIN JC, COPPOLA DJ, RUPP IP, SALLON SE, COHEN HJ: Comparative pharmacokinetic studies of three asparaginase preparations. J. Clin. Oncol. (1995) 11:1780-1786.
3. CAPIZZI RL, DAVIS R, POWELL B et al.: Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia - a Cancer and Leukemia Group B study. J. Clin. Oncol. (1988) 6:499-508.
4. HO D, WHITECAR J, LUCE J, FREI E: L-asparaginase requirement and the effect of L-asparaginase on the normal and leukemic human bone marrow. Cancer Res. (1970) 30:466-472.
5. CAPIZZI RL, BERTINO JR, SKEEL RT et al.: L-asparaginase: clinical, biochemical, pharmacological and immunological studies. Ann. Int. Med. (1971) 74:893-901.
6. KILLANDER D, DOHLWITZ A, ENGTEDT L et al.: Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer (1976) 37:220-228.
7. AVRAMIS VI, SENCER S, PERICLOU AP et al.: A randomized comparison of native Escherichia coli ASNase and polyethylene glycol conjugated ASNase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood (2002) 99:1986-1994.
8. ABUCHOWSKI A, KAZO GM, VERHOEST CR Jr et al.: Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem. Biophys. (1984) 7:175-186.
9. KIDD JG: Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum: I. Course of transplanted cancers of various kinds in mice and rats given pig serum, horse serum, or rabbit serum. J. Exp. Med. (1953) 98:565.
10. BROOME JD: Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects: I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilympoma substance. J. Exp. Med. (1963) 118:99.
11. DOLOWY WC, HENSEN DVM, CORNET J, SELLIN H: Toxic and antineoplastic effects of L-asparaginase. Cancer (1966) 19:1813.
12. ABUCHOWSKI A, KAZO GM, VERHOEST CR Jr et al.: Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem. Biophys. (1984) 7:175-186.
13. KAMISAKI Y, WADA H, YAGURA T, MATSUSHIMA A, INADA Y: Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol. J. Pharma. Exp. Ther. (1981) 216:410-414.
14. PATEL SS, BENFIELD P: Pegaspargase (polyethylene glycol-L-asparaginase). Clin. Immunother. (1996) 5:492-496.
15. WADA H, IMAMURA I, SAKO M et al.: Antitumor enzyme: polyethylene glycol-modified asparaginase. Ann. NY Acad. Sci. (1990) 61:95-108.
16. CAMPBELL HA, MASHBURN LT, BOYSE E et al.: Two L-asparaginases from E. coli B, their separation, purification and antitumor activity. Biochem. Genet. (1967) 6:721-730.
17. CHABNER BA, LOO TL: Enzyme therapy: L-asparaginase. In: Cancer Chemotherapy and Biotherapy: Principles and Practice. Chabner BA, Longo DL (Eds), Philadelphia: Lippincott-Raven (1996):485-492.
18. SWAIN AL, JASKOLSKI M, HOUSETT D et al.: Crystal structure of Escherichia coli L-asparaginase, an enzyme used in cancer therapy. Proc. Natl. Acad. Sci. USA (1993) 90:1474-1478.
19. 2 PEG-asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatr. Blood Cancer (2006) 46:18-25.
20. HAK LJ, RELLING MV, CHENG C et al.: Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia (2004) 18:1072-1077.
21. 2 BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols. Cancer Chemother. Pharmacol. (2002) 49:149-154.
22. DOUER D, YAMPOLSKY H, COHEN LJ et al.: Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults 55 years old or younger with newly diagnosed acute lymphoblastic leukemia. Blood (2007) 109:2744-2750.
23. 2 PEG-asparaginase i.v. in children with acute lymphoblastic leukemia. Klin. Padiatr. (2005) 217:321-326.
24. APPEL IM, PINHEIRO JP, DEN BOER ML et al.: Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia (2003) 17:2254-2256.
25. RlCCARDI R, HOLCENBERG JS, GLAUGIBER DL et al.: L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res. (1981) 41:4554-4556.
26. MILLER HK, SALSER JS, BALIS ME: Amino acid levels following L-asparaginase amidohydrolase (EC. 3.5.1.1.) therapy. Cancer Res. (1969) 29:183-187.
27. VIERA PINHEIRO JP, LANVERS C, WÜRTHWEIN G et al.: Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Leuk. Lymphoma (2002) 43:1911-1920.
28. SILVERMAN LB, STEVENSON K, NEUBERG D et al.: Intravenous PEG asparaginase during remission induction for childhood ALL. Proc. Am. Soc. Hematol. (2006) 108: (Abstract 1854).
29. PANOSYAN EH, SEIBEL NL, MARTIN-ARAGON S et al.: Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblas6c leukemia: Children's Cancer Group Study CCG-1961. J. Pediatr. Hematol. Oncol. (2004) 26:217-226.
30. RAMAKERS-VAN WOERDEN NL, PELTERS R, LOONEN AH et al.: TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood (2000) 96:1094-1099.
31. + pediatric ALL. Blood (2003) 101:2743-2747.
32. IWAMOTO S, MIHARA K, DOWNING JR et al.: Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J. Clin. Invest. (2007) 117:1049-1057.
33. KASPERS GJ, SMETS LA, PIETERS R et al.: Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood (1995) 85:751-756.
34. STAMS WA, DEN BOER ML, HOLLEMAN A et al.: Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood (2005) 105:4223-4225.
35. SU N, PAN YX, ZHOU M, HARVEY RC, HUNGER SP, KILBERG MS: Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines. Pediatr. Blood Cancer (2007) [Epub ahead of print].
36. DUBBERS A, WURTHWEIN G, MULLER HJ et al.: Asparagine synthetase activity in paediatric acute leukaemias: AML-M5 subtype shows lowest activity. Br. J. Haematol. (2000) 109:427-429.
37. OKADA S, HONGO T, YAMADA S et al.: In vitro efficacy of L-asparaginase in childhood acute myeloid leukaemia. Br. J. Haematol. (2003) 123:802-809.
38. FU CH, MARTIN-ARAGON S, WEINBERG KI et al.: Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein. Cancer Chemorher. Pharmacol. (2001) 48:123-133.
39. HOLLEMAN A, DEN BOER ML, DE MENEZES RX et al.: The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood (2006) 107:769-776.
40. KAWASHIMA K, TAKESHIMA H, HIGASHI Y et al.: High efficacy of monomethoxypolyethylene glycol-conjugated L-asparaginase (PEG2-ASP) in two patient with hematological malignancies. Leuk. Res. (1991) 15:525-530.
41. AGRAWAL NR, BUKOWSKI RM, RYBICKI LA et al.: A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma. Cancer (2003) 98:94-99.
42. MUSS HB, SPELL N, SCUDIERY D et al.: A Phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphoma. Invest. N. Drugs (1990) 8:125-130.
43. KURRE HA, ETTINGER AG, VEENSTRA DL et al.: A pharmacoeconomic analysis of pegaspargase versos native Escherichia coli L-ASNase for the treatment of children with standard-risk acute lymphoblastic leukemia: the Children's Cancer Group Study (CCG-1962). J. Pediatr. Hematol. Oncol. (2002) 24:175-181.
44. SILVERMAN LB, GELBER RD, DALTON VK et al.: Improved outcome for children with acute lymphoblastic leukemia:results of Dana-Farber Consortium protocol 91-01. Blood (2001) 97:1211-1218.
45. NESBIT M, CHARD R, EVANS A et al.: Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am. J. Pediatr. Hematol. Oncol. (1979) 1:9-13.
46. ALVAREZ OA, ZIMMERMAN G: Pegaspargase-induced pancreatitis. Med. Pediatr. Oncol. (2000) 34:200-205.
47. ATHALE UH, SICILIANO SA, CROTHER M et al.: Thromboenbolism in children with actue lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br. J. Hematol. (2005) 129:803-810.
48. CAPIZZI RL: Asparaginase revisited. Leuk. Lymphoma (1993) 10:147-150.
49. PACKAGE INSERT: Oncaspar (pegaspargase). Bridgewater, NJ: Enzon Pharmaceuticals, Inc. (2006).
50. TAYLOR CW, DORR RT, FANTA P: A Phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors. Cancer Chemother. Pharmacol. (2001) 47:83-88.
51. CAPIZZI RI.: Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cells. Cancer Treat. Rep. (1981) 65(Suppl. 4):115-121.
52. SUR P, FERNANDES DJ, KUTE TE et al.: L-asparaginase-induced modulation of methotrexate polyglutamylation in murine leukemia L5178Y. Cancer Res. (1987) 47:1313-1318.
53. KURTZBERG J, FREIDMAN H, ASSELIN B et al.: The use of polyethylene glycol-conjugated L-asparaginase (PEG-ASP) in pediatric patients with prior hypersensitivity to native L-asparaginase. Proc. Am. Soc. Clin. Oncol. (1990) 9:219 (Abstract).
54. KURTZBERG J, ASSELIN B, BERG S et al.: Pharmacokinetics of PEG-L-asparaginase in pediatric patients with known hypersensitivity to native L-asparaginase. Proc. Am. Assoc. Cancer Res. (1992) 33:210 (Abstract).